Insmed (INSM) Receivables (2010 - 2026)
Insmed (INSM) posted quarterly Receivables of $178.6 million for Q1 2026, up 273.97% year-over-year from $47.7 million in Q1 2025, and up 26.76% quarter-over-quarter from $140.9 million in Q4 2025.
Insmed (INSM) Receivables (2010 - 2026) Analysis & Trends
Insmed's Receivables history runs 11 years deep, the most recent figure standing at $178.6 million for Q1 2026.
- In Q1 2026, Receivables rose 273.97% year-over-year to $178.6 million; the TTM figure through Mar 2026 stood at $178.6 million (up 273.97% YoY), while the FY2025 annual figure was $140.9 million, up 170.82% from the prior year.
- Receivables for Q1 2026 stood at $178.6 million, up from $140.9 million in the prior quarter.
- The five-year high for Receivables was $178.6 million in Q1 2026, with the low at $25.7 million in Q1 2022.
- The 5-year median for Receivables is $40.3 million (2024), against an average of $53.5 million.
- The sharpest annual moves came in 2023 and 2026: Receivables grew 4.97% in 2023, then soared 273.97% in 2026.
- Insmed's Receivables stood at $29.7 million in 2022, then surged by 38.62% to $41.2 million in 2023, then advanced by 26.28% to $52.0 million in 2024, then surged by 170.82% to $140.9 million in 2025, then advanced by 26.76% to $178.6 million in 2026.
- Business Quant data shows INSM's Receivables at $178.6 million in Q1 2026, $140.9 million in Q4 2025, and $65.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 215.33 Mn |
| Mar 31, 2026 | 178.56 Mn |
| Dec 31, 2025 | 140.86 Mn |
| Sep 30, 2025 | 65.26 Mn |
| Jun 30, 2025 | 55.03 Mn |
| Mar 31, 2025 | 47.75 Mn |
| Dec 31, 2024 | 52.01 Mn |
| Sep 30, 2024 | 42.32 Mn |
| Jun 30, 2024 | 40.30 Mn |
| Mar 31, 2024 | 37.16 Mn |
| Dec 31, 2023 | 41.19 Mn |
| Sep 30, 2023 | 35.58 Mn |
| Jun 30, 2023 | 30.95 Mn |
| Mar 31, 2023 | 30.52 Mn |
| Dec 31, 2022 | 29.71 Mn |
| Sep 30, 2022 | 27.40 Mn |
| Jun 30, 2022 | 29.48 Mn |
| Mar 31, 2022 | 25.72 Mn |
| Dec 31, 2021 | 24.35 Mn |
| Sep 30, 2021 | 19.32 Mn |